Holen Sie sich die Stockscreener-App
1.08
1.89%
0.02
Handel nachbörslich:
1.11
0.03
+2.78%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTSO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.06
Offen:
$1.05
24-Stunden-Volumen:
50,770
Relative Volume:
0.30
Marktkapitalisierung:
$67.78M
Einnahmen:
$33.79M
Nettoeinkommen (Verlust:
$-18.67M
KGV:
-3.0151
EPS:
-0.3582
Netto-Cashflow:
$-19.17M
1W Leistung:
+19.73%
1M Leistung:
+1.89%
6M Leistung:
-17.56%
1J Leistung:
+20.67%
1-Tages-Spanne:
$1.04
$1.095
1-Wochen-Bereich:
$0.8932
$1.22
52-Wochen-Spanne:
$0.7101
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Firmenname
Cytosorbents Corp
Sektor
Branche
Telefon
973-329-8885
Adresse
305 COLLEGE ROAD EAST, PRINCETON, NJ
Vergleichen Sie CTSO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
1.08 | 66.37M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-07 | Eingeleitet | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2020-09-17 | Eingeleitet | Jefferies | Buy |
| 2020-09-01 | Eingeleitet | SVB Leerink | Outperform |
| 2017-08-08 | Bestätigt | Maxim Group | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-05-24 | Eingeleitet | Maxim Group | Buy |
| 2015-10-29 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | Bestätigt | MLV & Co | Buy |
| 2015-04-01 | Bestätigt | MLV & Co | Buy |
| 2015-03-05 | Eingeleitet | MLV & Co | Buy |
| 2015-02-25 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-01-27 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Cytosorbents Corp Aktie (CTSO) Neueste Nachrichten
What recovery options are there for Cytosorbents CorporationRisk Management & Technical Pattern Based Buy Signals - Newser
How sentiment analysis helps forecast Cytosorbents CorporationQuarterly Portfolio Report & Long-Term Safe Return Strategies - Newser
Is now a turning point for Cytosorbents Corporation2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Cytosorbents Corp Q2 2025 Earnings Call Highlights - TipRanks
Why Cytosorbents Corporation stock attracts strong analyst attentionFree ROI Driven Equity Selection With Safety - Newser
Published on: 2025-08-12 20:31:12 - Newser
Sector ETF performance correlation with Cytosorbents Corporation [July 2025 Drop Watch]Risk Controlled Swing Trade Alerts - Newser
Is this a good reentry point in Cytosorbents CorporationFree Daily Chart Pattern Stock Forecast - Newser
Is Cytosorbents Corporation reversing from oversold territoryForecast Model for Intraday Buy Signals - Newser
Cytosorbents Corporation (NASDAQ:CTSO) Q2 2025 Earnings Call Transcript - Insider Monkey
Exit strategy if you’re trapped in Cytosorbents CorporationEquity Market Return Forecast Model Update - Newser
Can volume confirm reversal in Cytosorbents CorporationExit Strategy Guide With Risk Control Plan - Newser
What institutions are buying Cytosorbents Corporation stock now5-Year Price Trend Summary and Analysis - Newser
Will Cytosorbents Corporation continue its uptrendFree Long Hold Safe Return Strategy - Newser
Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Cytosorbents Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
How to forecast Cytosorbents Corporation trends using time seriesHigh Return Strategy with Low Risk - Newser
How Cytosorbents Corporation stock performs during market volatilityTechnical Screener for High Growth Stocks - Newser
Earnings call transcript: CytoSorbents Q2 2025 revenue miss, stock dips By Investing.com - Investing.com Canada
Earnings call transcript: CytoSorbents Q2 2025 revenue miss, stock dips - Investing.com
CytoSorbents Corp (CTSO) Q2 2025 Earnings Call Highlights: Strat - GuruFocus
CytoSorbents Reports Positive Q2 2025 Financial Results - TipRanks
Cytosorbents Corp reports results for the quarter ended June 30Earnings Summary - TradingView
CytoSorbents: Q2 Earnings Snapshot - San Antonio Express-News
CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Reversal indicators forming on Cytosorbents Corporation stockFree Wealth Building Stock Market Ideas - Newser
What MACD signals say about Cytosorbents CorporationWeekly Market Direction and Sector Summary - Newser
Cytosorbents Corp expected to post a loss of 5 cents a shareEarnings Preview - TradingView
How to recover losses in Cytosorbents Corporation stockBuy and Hold Return Summary with Charts - Newser
Tools to assess Cytosorbents Corporation’s risk profileFree Real Time Alerts Based on AI Prediction - Newser
Is Cytosorbents Corporation stock overvalued or undervaluedAchieve rapid portfolio growth with expert guidance - Jammu Links News
Is it the right time to buy Cytosorbents Corporation stockBuild a portfolio that delivers consistent profits - Jammu Links News
Breakthrough Sepsis Treatment: CytoSorb Therapy Achieves 70% Survival Rate in Latest Clinical Studies - Stock Titan
CytoSorbents Leads a New Era in Sepsis Treatment - Nasdaq
What makes Cytosorbents Corporation stock price move sharplyWeekly High Conviction Trade Setup Analysis - Newser
Should you wait for a breakout in Cytosorbents CorporationFree Wealth Building Stock Market Ideas - Newser
Medical Tech Leader CytoSorbents Sets Q2 2025 Earnings Call: Key Updates Expected on ICU Treatment Solutions - Stock Titan
Why is Cytosorbents Corporation stock attracting strong analyst attentionHigh-profit stock alerts - Jammu Links News
Finanzdaten der Cytosorbents Corp-Aktie (CTSO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):